These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 9220058

  • 21. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence.
    Brown RT, Amler RW, Freeman WS, Perrin JM, Stein MT, Feldman HM, Pierce K, Wolraich ML, American Academy of Pediatrics Committee on Quality Improvement, American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder.
    Pediatrics; 2005 Jun; 115(6):e749-57. PubMed ID: 15930203
    [Abstract] [Full Text] [Related]

  • 22. A prospective open trial of guanfacine in children with pervasive developmental disorders.
    Scahill L, Aman MG, McDougle CJ, McCracken JT, Tierney E, Dziura J, Arnold LE, Posey D, Young C, Shah B, Ghuman J, Ritz L, Vitiello B.
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):589-98. PubMed ID: 17069547
    [Abstract] [Full Text] [Related]

  • 23. A comparative analysis of antidepressants and stimulants for the treatment of adults with attention-deficit hyperactivity disorder.
    Higgins ES.
    J Fam Pract; 1999 Jan; 48(1):15-20. PubMed ID: 9934377
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder.
    Himpel S, Banaschewski T, Heise CA, Rothenberger A.
    Expert Opin Drug Saf; 2005 Mar; 4(2):311-21. PubMed ID: 15794722
    [Abstract] [Full Text] [Related]

  • 27. Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial.
    Akhondzadeh S, Tavakolian R, Davari-Ashtiani R, Arabgol F, Amini H.
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Aug; 27(5):841-5. PubMed ID: 12921918
    [Abstract] [Full Text] [Related]

  • 28. Attention-deficit hyperactivity disorder: the pharmacist's role.
    Levin GM.
    Am Pharm; 1995 Nov; NS35(11):10-20. PubMed ID: 8533716
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Non-stimulant treatment of attention-deficit/hyperactivity disorder.
    Pliszka SR.
    CNS Spectr; 2003 Apr; 8(4):253-8. PubMed ID: 12679740
    [Abstract] [Full Text] [Related]

  • 31. Attention-deficit/hyperactivity disorder: a life-span perspective.
    Biederman J.
    J Clin Psychiatry; 1998 Apr; 59 Suppl 7():4-16. PubMed ID: 9680048
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Mechanism of action of agents used in attention-deficit/hyperactivity disorder.
    Wilens TE.
    J Clin Psychiatry; 2006 Apr; 67 Suppl 8():32-8. PubMed ID: 16961428
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Attention deficit hyperactivity disorder across the lifespan: the child, adolescent, and adult.
    Greydanus DE, Pratt HD, Patel DR.
    Dis Mon; 2007 Feb; 53(2):70-131. PubMed ID: 17386306
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.